ArticleCureus2025
Clinical Presentation and Management of Breast Cancer With Vertebral Metastasis: A Retrospective Cohort Study in Tunisia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Breast cancer is the most common malignancy affecting women, and vertebral metastases are a frequent complication. This study aimed to examine the clinical and anatomical characteristics, therapeutic management, and prognostic factors associated with vertebral metastases from breast carcinomas in patients from south-eastern Tunisia. Materials and methods This descriptive cohort analytical study utilized retrospectively collected data and was conducted in the medical oncology and orthopaedic surgery departments at the Gabes University Hospital over a five-year period, from January 2015 to December 2019. Clinical, pathological, and therapeutic data were statistically analysed to identify prognostic factors influencing overall survival. Results The study included 57 patients with a median age of 48 years. Metastases were metachronous in 41 patients (71.9%) and synchronous in 16 (28.1%). Tumours were classified as T4 in 42.1% of study cases. Spinal metastases mainly affected two vertebral levels in 61.4% of patients and involved three vertebrae in 70.2% of cases. Spinal cord compression was the most common complication (24.6%). Extravertebral bone, pulmonary, hepatic, and brain metastases were observed in 80.7%, 43.9%, 49.1%, and 12.3% of patients. Hormone receptors and human epidermal growth factor receptor (HER2) were expressed in 73.3% and 19.3% of cases, respectively. No patients underwent surgery for spinal metastasis. Breast radiotherapy was administered in 52.6% of cases, of which 42.1% targeted spinal metastases. Median survival was 28 months. Overall survival at three and five years was 38.6% and 22.7%, respectively. Significant prognostic factors for overall survival included age (p=0.041) and metastatic disease at diagnosis (p=0.01). Conclusion Vertebral bone metastases can compromise the neurological outcomes. However, various systemic and local therapeutic options are available for managing vertebral metastasis. A multidisciplinary approach is essential to optimise strategies and improve prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.